Back to Search Start Over

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.

Authors :
Claudia Brogna
Giorgia Coratti
Marika Pane
Valeria Ricotti
Sonia Messina
Adele D'Amico
Claudio Bruno
Gianluca Vita
Angela Berardinelli
Elena Mazzone
Francesca Magri
Federica Ricci
Tiziana Mongini
Roberta Battini
Luca Bello
Elena Pegoraro
Giovanni Baranello
Stefano C Previtali
Luisa Politano
Giacomo P Comi
Valeria A Sansone
Alice Donati
Enrico Bertini
Francesco Muntoni
Nathalie Goemans
Eugenio Mercuri
on behalf on the International DMD group
Source :
PLoS ONE, Vol 14, Iss 6, p e0218683 (2019)
Publication Year :
2019
Publisher :
Public Library of Science (PLoS), 2019.

Abstract

IntroductionThe aim of this international collaborative effort was to report 36-month longitudinal changes using the 6MWT in ambulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53.Materials and methodsOf the 92 patients included in the study, 24 had deletions amenable to skip exon 44, 27 exon 45, 18 exon 51, and 28 exon 53. Five patients with a single deletion of exon 52 were counted in both subgroups skipping exon 51 and 53.ResultsThe difference between subgroups amenable to skip different exons was not significant at 12 months but became significant at both 24 (p≤0.05) and 36 months (p≤0.01).DiscussionMutations amenable to skip exon 53 had lower baseline values and more negative changes than the other subgroups while those amenable to skip exon 44 had better results both at baseline and at follow up. Deletions amenable to skip exon 45 were associated with a more variable pattern of progression. Single exon deletions were more often associated with less drastic changes but this was not always true in individual cases.ConclusionOur results confirm that the progression of disease can differ between patients with different deletions, although the changes only become significant from 24 months onwards. This information is relevant because there are current clinical trials specifically targeting patients with these subgroups of mutations.

Subjects

Subjects :
Medicine
Science

Details

Language :
English
ISSN :
19326203
Volume :
14
Issue :
6
Database :
Directory of Open Access Journals
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
edsdoj.3932d113fabe49fdac298f216fdc150a
Document Type :
article
Full Text :
https://doi.org/10.1371/journal.pone.0218683